Collegium to Report Fourth Quarter and Full-Year 2025 Financial Results on February 26, 2026
Rhea-AI Summary
Collegium (Nasdaq: COLL) will report fourth-quarter and full-year 2025 financial results before the market opens on Thursday, February 26, 2026. The company will host a live conference call and webcast at 8:00 a.m. ET the same day. An audio webcast will be available on the Investors section of the company website and replayable approximately two hours after the event.
Positive
- None.
Negative
- None.
News Market Reaction – COLL
On the day this news was published, COLL gained 0.31%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
COLL fell 3.44% while peers were mixed: PCRX up 2.16%, HROW up 1.35%, EVO down 1.42%, and AMPH roughly flat. Moves do not indicate a unified sector trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 15 | Medical conference data | Positive | +0.7% | Real‑world data posters on Jornay PM at APSARD 2026 conference. |
| Jan 8 | Guidance and update | Positive | +3.2% | Issued 2026 revenue and EBITDA guidance plus business update and credit facility detail. |
| Dec 30 | Debt refinancing | Positive | -4.8% | Closed $980M syndicated credit facility and refinanced prior term loan. |
| Nov 12 | Investor conferences | Neutral | +5.6% | Announced participation in multiple late‑2025 investor conferences with webcasts. |
| Nov 6 | Earnings and guidance | Positive | +13.4% | Reported record Q3 2025 results and raised full‑year 2025 guidance. |
Recent news tied to earnings, guidance, and growth initiatives has often seen positive price alignment, with debt refinancing the main recent divergence.
Over the last few months, Collegium has reported record Q3 2025 results with raised 2025 guidance, provided detailed 2026 revenue and EBITDA guidance, and closed a large syndicated credit facility. The stock reacted positively to earnings and guidance updates, including a 13.42% move after Q3 results and 3.22% after 2026 guidance, while the refinancing announcement coincided with a 4.75% decline. Conference participation and real‑world data presentations also drew modest positive reactions, framing today’s earnings date notice within an established communications cadence.
Market Pulse Summary
This announcement sets expectations for the upcoming Q4 and full‑year 2025 earnings release and conference call. In recent quarters, Collegium has highlighted record net revenue, raised 2025 guidance, and provided detailed 2026 targets, with generally positive share reactions to operational updates. The scheduled call gives investors a defined point to compare new results against prior guidance and the impact of the recently closed syndicated credit facility. Attention will likely center on revenue growth, profitability trends, and cash generation versus the last reported quarter.
AI-generated analysis. Not financial advice.
STOUGHTON, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report fourth quarter and full-year 2025 financial results before the market opens on Thursday, February 26, 2026. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET.
Conference Call Information
To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q4 2025 Earnings Call.” An audio webcast will be accessible from the Investors section of the Company’s website: www.collegiumpharma.com. The webcast will be available for replay on the Company’s website approximately two hours after the event.
About Collegium Pharmaceutical, Inc.
Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and a rapidly growing neuropsychiatry business driven by Jornay PM®, a differentiated treatment for ADHD. Collegium’s strategy includes growing its commercial portfolio, with Jornay PM as the lead growth driver, and deploying capital in a disciplined manner. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at www.collegiumpharma.com.
Investor Contacts:
Ian Karp
Head of Investor Relations
ir@collegiumpharma.com
Danielle Jesse
Director, Investor Relations
ir@collegiumpharma.com
Media Contact:
Jessica Cotrone
Senior Vice President, Communications & Corporate Affairs
communications@collegiumpharma.com
FAQ
When will Collegium (COLL) report fourth-quarter and full-year 2025 results?
What time is the Collegium (COLL) Q4 2025 earnings call and webcast?
How can investors access the Collegium (COLL) Q4 2025 earnings call?
Will a replay of the Collegium (COLL) Q4 2025 webcast be available?
Where is the Collegium (COLL) earnings webcast hosted online?
